Cannabis and Cannabinoid Research最新文献

{"title":"Neighborhood Sociodemographic Correlates of Cannabis Dispensary Availability in States with Legalized Adult Recreational Use, United States, 2021.","authors":"Bryce C Lowery, Madison R E Swayne, Amanda Y Kong","doi":"10.1089/can.2024.0065","DOIUrl":"https://doi.org/10.1089/can.2024.0065","url":null,"abstract":"<p><p><b>Introduction:</b> The availability of recreational cannabis in the United States has increased dramatically. Neighborhood cannabis dispensary availability may increase problematic use. State and local studies suggest that cannabis dispensary availability may be correlated with neighborhood sociodemographic characteristics. We provide a national-level examination of census tract (CT) sociodemographic characteristic correlates with the availability of cannabis dispensaries in 18 U.S. states that have legalized adult recreational cannabis use. <b>Methods:</b> We downloaded the locations of cannabis dispensaries (<i>N</i> = 3,167) from Weedmaps in November 2021. We downloaded ethnic, racial, and socioeconomic estimates from the U.S. Census and categorized CTs into quintiles (Q), where Q1 represents the CTs with the lowest percentage of a variable and Q5 represents CTs with the highest. We fit unadjusted generalized linear mixed models to examine associations between quintiles of each sociodemographic characteristic and the presence of at least one dispensary (vs. none). <b>Results:</b> CTs with a greater percentage of Black residents had a higher odds of having at least one cannabis dispensary (vs. none) across all quintiles. For example, compared to CTs with the lowest percentage of Black residents (Q1), CTs with the greatest percentage of Black residents (Q5) had 2.07 (95% CI: 1.70-2.52) times the odds of having at least one dispensary versus none. We observed a similar pattern of a greater likelihood of a CT having a dispensary (vs. none) as the percentage of Hispanic/Latine residents and percentage of individuals living below the federal poverty line increased across all quintiles. In contrast, as the percentage of homeowner-occupied housing increased across all quintiles, there were lower odds of having at least one dispensary (vs. none). For example, CTs with the highest percentage of homeowner-occupied housing (vs. lowest) had 0.21 (95% CI: 0.17-0.26) times the odds of having at least one dispensary vs. none. <b>Discussion/Conclusions:</b> Differences in cannabis dispensary availability exist by neighborhood sociodemographic composition. The growing acceptance of cannabis, concern about public health and safety, and the proliferation of adult recreational use laws offer local and state policymakers an opportunity to engage local communities in shared decision-making about the location of dispensaries.</p>","PeriodicalId":9386,"journal":{"name":"Cannabis and Cannabinoid Research","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143647352","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"<i>Letter to the Editor:</i> Response to Dr. Mousavi's Comments on Ogunsola et al.","authors":"Ayobami S Ogunsola, Samuel Smith, Eniola A Olatunji, Mercy C Udeh, Ibraheem M Karaye","doi":"10.1089/can.2025.0008","DOIUrl":"https://doi.org/10.1089/can.2025.0008","url":null,"abstract":"","PeriodicalId":9386,"journal":{"name":"Cannabis and Cannabinoid Research","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2025-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143584809","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Pharmacokinetics and Pharmacodynamics of a Hemp-Derived \"Full-Spectrum\" Oral Cannabinoid Product with a 1:1 Ratio of Cannabidiol to Cannabidiolic Acid and Delta-9-Tetrahydrocannabinol to Delta-9-Tetrahydrocannabinolic Acid: A Double-Blind, Placebo-Controlled, Within-Subjects Human Laboratory Study.","authors":"Harrison J Elder, C Austin Zamarripa, McKenna Klausner, Joseph Wakshlag, Robert Davis, Beth Dresser, Christian Kjaer, Elise M Weerts, Ryan Vandrey, Tory R Spindle","doi":"10.1089/can.2024.0187","DOIUrl":"https://doi.org/10.1089/can.2024.0187","url":null,"abstract":"<p><p><b>Aim:</b> To examine the acute pharmacokinetics (PK) and pharmacodynamics (PD) of a patented oral cannabinoid product containing a botanical hemp-derived \"full-spectrum\" extract with an approximate 1:1 ratio of cannabidiol (CBD) to cannabidiolic acid (CBDA) and delta-9-tetrahydrocannabinol (THC) to delta-9-tetrahydrocannabinolic acid (THCA). <b>Methods:</b> Healthy adults (<i>n</i> = 15) ingested soft gels containing 0 (placebo), and approximately 1, 2, and 4 mg/kg of total cannabinoids (combination of CBD, CBDA, THC, THCA, and other minor cannabinoids) in an ascending-dose order in four experimental sessions separated by ≥1 week (the placebo condition occurred randomly within the dose sequence). Mean doses (mg) of primary cannabinoids in the active drug conditions were: 1 mg/kg condition (CBD = 41.1, CBDA = 43.7, THC = 2.2, THCA = 1.6), 2 mg/kg condition (CBD = 73.4, CBDA = 77.9, THC = 3.9, THCA = 2.9), and 4 mg/kg condition (CBD = 134.5, CBDA = 142.8, THC = 7.2, THCA = 5.3). PD outcomes (subjective, cognitive, and physiological effects) were measured before and repeatedly for 8 h after dosing. Plasma specimens were collected throughout the 8-h sessions and at 24- and 48-h post-dosing. PK outcomes included peak plasma concentration (<i>C</i>_max) and time to maximum concentration (<i>T</i>_max). <b>Results:</b> For PD outcomes, few differences were observed between 1 mg/kg and placebo. However, relative to placebo, 2 mg/kg and 4 mg/kg produced small to moderate increases in subjective drug effects, including abuse liability items (e.g., \"like\"), and 4 mg/kg also impaired working memory performance. Generally, PD effects peaked 3-5 h post-dosing and returned to baseline by 8 h. Dose-orderly increases in <i>C</i>_max were observed for CBD, CBDA, THC, THCA, and their respective metabolites (e.g., 7-COOH-CBD, THCCOOH), which were often detectable 48 h post-dosing. Across all doses, <i>C</i>_max for CBDA and THCA was 19-25-fold higher and <i>T</i>_max was up to 2-fold earlier compared with CBD and THC, respectively. <b>Conclusions:</b> Acute administration of a \"full-spectrum\" hemp-derived cannabinoid product produced dose-orderly effects; the highest dose elicited several adverse events and produced moderate cognitive impairment and subjective intoxication, despite containing a relatively low dose of THC (mean: 7.2 mg). Carboxylated cannabinoids (e.g., CBDA) exhibited substantially greater bioavailability and faster absorption compared with decarboxylated cannabinoids (e.g., CBD). Additional systematic research is needed to characterize how constituent profile impacts the effects of cannabinoid products, and more studies directly comparing carboxylated and decarboxylated compounds appear warranted.</p>","PeriodicalId":9386,"journal":{"name":"Cannabis and Cannabinoid Research","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143555867","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Chronic Disease Symptoms Self-Managed by Cannabis During the COVID-19 Pandemic: Results from the COVID-19 Cannabis Health Study.","authors":"Nicole O'Dell, Amrit Baral, Marvin Reid, Bria-Necole A Diggs, Jessica Y Islam, Marlene Camacho-Rivera, Johis Ortega, Denise C Vidot","doi":"10.1089/can.2023.0234","DOIUrl":"https://doi.org/10.1089/can.2023.0234","url":null,"abstract":"<p><p><b>Background:</b> The COVID-19 pandemic has impacted billions of people worldwide, particularly those with chronic health conditions, and has been associated with increases in substance use, including cannabis. The purpose of this study was to estimate the prevalence of cannabis use for symptom management of chronic health conditions during the COVID-19 pandemic. <b>Methods:</b> The COVID-19 Cannabis Health Study is an ongoing study among adults ≥18 who self-report cannabis use. Analyses included 1,466 responses received between March 21, 2020, and March 23, 2022, from participants who self-reported cannabis use and a chronic health condition. We examined comorbidities, symptoms managed with cannabis during the COVID-19 pandemic, and fear regarding COVID-19 diagnosis and transmission using the COVID-19 Cannabis Health Questionnaire. Descriptive statistics, Chi-squared, and T-tests were conducted. Results were stratified by those who reported using cannabis to manage a chronic health condition (medicinal cannabis user, <i>n</i> = 1,333) and those who did not use cannabis to manage chronic health condition (non-medicinal cannabis user, <i>n</i> = 133). <b>Results:</b> Most (90.9%, <i>n</i> = 1,333) of the total sample (mean age: 47.1 years [standard deviations {SD} = 15.0]) reported using cannabis to manage a chronic health condition, of which 46.1% (<i>n</i> = 615) reported having a medical card/recommendation, and 4.6% received recommendations to use cannabis to manage COVID-19 from health professionals. There were significant differences in age, gender, race/ethnicity, and education by medicinal cannabis use status. Comorbidities prevalent among medicinal cannabis consumers were mental health-related (66.1%), pain (58.5%), cardiometabolic-related (30.5%), immune-related (21.9%), and respiratory-related (20.8%). The most reported symptoms self-managed with cannabis during the pandemic were sleep (69.2%), chronic noncancer pain (49.7%), acute pain (46.5%), headaches/migraines (39.0%), muscle spasms (33.6%), nausea/vomiting (30.6%), and appetite stimulant (29.9%). There were no statistical differences in COVID-19 testing, fear of diagnosis, fear of transmission, or isolation due to COVID-19 between medicinal and nonmedicinal cannabis consumers in this sample. <b>Conclusions:</b> The perceived therapeutic benefit of cannabis during the COVID-19 pandemic is evident by the high prevalence of adults who reported using cannabis for medicinal reasons despite no recommendation from their health provider. Research is necessary to understand the prospective impact of cannabis use for self-management of chronic disease, especially within the context of COVID-19.</p>","PeriodicalId":9386,"journal":{"name":"Cannabis and Cannabinoid Research","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2025-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143498940","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence of Gastrointestinal Adverse Events of Therapeutic Cannabinoids in Children: A Systematic Review and Meta-Analysis.","authors":"Parsa Karimi, Maria Sunil, Russell Leong, Jose Luis Ramirez-GarciaLuna, Elyanne Ratcliffe, Gregorio Zuniga-Villanueva","doi":"10.1089/can.2024.0104","DOIUrl":"https://doi.org/10.1089/can.2024.0104","url":null,"abstract":"<p><p><b>Introduction:</b> The endocannabinoid system plays a crucial role in gastrointestinal homeostasis; although some gastrointestinal adverse events have been reported with therapeutic cannabinoids in children, the complete profile of gastrointestinal adverse events in the pediatric population remains unknown. Through a systematic review and meta-analysis, we aimed to identify the prevalence of gastrointestinal adverse events from therapeutic cannabinoids in children. <b>Materials and Methods:</b> A literature search of OVID MEDLINE, EMBASE, CINAHL, Web of Science, and The Cochrane Library was performed from inception to May 19, 2023. Selected studies included randomized controlled trials, retrospective cohort studies, uncontrolled before-after studies, and observational retrospective studies in English, French, or Spanish that reported gastrointestinal adverse events in the pediatric population under therapeutic cannabinoid interventions. The study was registered with PROSPERO and followed the Preferred Reporting Items for Systematic Reviews and Meta-analyses reporting guidelines. A random-effects model was used to pool and analyze the extracted data. Extracted data included the presence of adverse gastrointestinal events by analyzing the type of cannabinoid, duration of treatment, dosage, and type of study. A subgroup meta-analysis was also performed, focusing on patients' conditions. <b>Results:</b> Twenty-five studies were included, comprising 1,201 pediatric patients receiving therapeutic cannabinoids, of whom 451 experienced gastrointestinal adverse events, representing a cumulative prevalence of 33.91% (95% confidence interval [CI]: 21.49% to 49.04%). Interventional studies reported a higher prevalence of GI adverse events (47.36%; 95% CI: 31% to 64%) compared with observational studies (17.6%; 95% CI: 8.5% to 32.7%). As most studies focused on patients with epilepsy, a subanalysis was performed within this population, revealing that patients with Dravet syndrome had a higher prevalence of diarrhea compared with other types of epilepsy (21.75%; 95% CI: 8.52% to 45.34% vs. 5.95%; 95% CI: 3.11% to 11.1%). <b>Discussion:</b> This systematic review and meta-analysis showed a high prevalence of gastrointestinal adverse events in children receiving therapeutic cannabinoids, with some populations, such as those with Dravet syndrome, being at higher risk than others. With the increased public discourse of cannabinoids being \"natural\" and mistakenly equating them as \"risk-free,\" this information can help clinicians educate patients and the broader public on the adverse effects profile of these treatments.</p>","PeriodicalId":9386,"journal":{"name":"Cannabis and Cannabinoid Research","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2025-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143448238","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Cannabis Gray Market: A Case for Cannabis Regulatory Science Research.","authors":"Nicolas J Schlienz, Nicholas J Felicione, Dustin C Lee, Richard J O'Connor, Danielle M Smith","doi":"10.1089/can.2023.0278","DOIUrl":"10.1089/can.2023.0278","url":null,"abstract":"<p><p>The cannabis gray market poses significant public health concerns and remains a major threat to consumer and/or potential consumer uptake of regulated cannabis markets in jurisdictions with legal state-sponsored cannabis programs. In this perspective, we provide an overview of the cannabis gray market, and describe an integrated epidemiological and regulatory science framework to study the gray market. Using tobacco regulatory science as a guide, we introduce example cannabis regulatory science research activities as a means to improve the field's understanding of the cannabis gray market. Cannabis regulatory science is a developing field that can improve our understanding of the cannabis regulatory ecosystem and provide regulatory officials and policymakers alike with much needed data to inform regulatory decision-making and improve the success and uptake of state-sponsored cannabis programs.</p>","PeriodicalId":9386,"journal":{"name":"Cannabis and Cannabinoid Research","volume":" ","pages":"6-10"},"PeriodicalIF":3.1,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141466331","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Beneficial Consequences of One-Month Oral Treatment with Cannabis Oil on Cardiac Hypertrophy and the Mitochondrial Pool in Spontaneously Hypertensive Rats.","authors":"Erica Vanesa Pereyra, Joshua Godoy Coto, Jorge Omar Velez Rueda, Fiorella Anabel Cavalli, Luisa Fernanda González Arbelaez, Juliana Catalina Fantinelli, Oswaldo Aranda, Jorge Esteban Colman Lerner, Enrique Leo Portiansky, Susana Maria Mosca, Irene Lucia Ennis","doi":"10.1089/can.2024.0066","DOIUrl":"10.1089/can.2024.0066","url":null,"abstract":"<p><p><b>Introduction:</b> It has been demonstrated the dysregulation of the cardiac endocannabinoid system in cardiovascular diseases. Thus, the modulation of this system through the administration of phytocannabinoids present in medicinal cannabis oil (CO) emerges as a promising therapeutic approach. Furthermore, phytocannabinoids exhibit potent antioxidant properties, making them highly desirable in the treatment of cardiac pathologies, such as hypertension-induced cardiac hypertrophy (CH). <b>Objective:</b> To evaluate the effect of CO treatment on hypertrophy and mitochondrial status in spontaneously hypertensive rat (SHR) hearts. <b>Methods:</b> Three-month-old male SHR were randomly assigned to CO or olive oil (vehicle) oral treatment for 1 month. We evaluated cardiac mass and histology, mitochondrial dynamics, membrane potential, area and density, myocardial reactive oxygen species (ROS) production, superoxide dismutase (SOD), and citrate synthase (CS) activity and expression. Data are presented as mean ± SEM (n) and compared by <i>t</i>-test, or two-way ANOVA and Bonferroni <i>post hoc</i> test were used as appropriate. <i>p</i> < 0.05 was considered statistically significant. <b>Results:</b> CH was reduced by CO treatment, as indicated by the left ventricular weight/tibia length ratio, left ventricular mass index, myocyte cross-sectional area, and left ventricle collagen volume fraction. The ejection fraction was preserved in the CO-treated group despite the persistence of elevated systolic blood pressure and the reduction in CH. Mitochondrial membrane potential was improved and mitochondrial biogenesis, dynamics, area, and density were all increased by treatment. Moreover, the activity and expression of the CS were enhanced by treatment, whereas ROS production was decreased and the antioxidant activity of SOD increased by CO administration. <b>Conclusion:</b> Based on the mentioned results, we propose that 1-month oral treatment with CO is effective to reduce hypertrophy, improve the mitochondrial pool and increase the antioxidant capacity in SHR hearts.</p>","PeriodicalId":9386,"journal":{"name":"Cannabis and Cannabinoid Research","volume":" ","pages":"e134-e144"},"PeriodicalIF":3.1,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141975124","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Neonatal Cannabidiol Exposure Impairs Spatial Memory and Disrupts Neuronal Dendritic Morphology in Young Adult Rats.","authors":"Meetu Wadhwa, Gregory A Chinn, Jennifer M Sasaki Russell, Judith Hellman, Jeffrey W Sall","doi":"10.1089/can.2024.0010","DOIUrl":"10.1089/can.2024.0010","url":null,"abstract":"<p><p><b>Introduction:</b> Early life is a sensitive period for brain development. Perinatal exposure to cannabis is increasingly linked to disruption of neurodevelopment; however, research on the effects of cannabidiol (CBD) on the developing brain is scarce. In this study, we aim to study the developmental effects of neonatal CBD exposure on behavior and dendritic architecture in young adult rats. <b>Materials and Methods:</b> Male and female neonatal Sprague Dawley rats were treated with CBD (50 mg/kg) intraperitoneally on postnatal day (PND) 1, 3, and 5 and evaluated for behavioral and neuronal morphological changes during early adulthood. Rats were subjected to a series of behavioral tasks to evaluate long-term effects of neonatal CBD exposure, including the Barnes maze, open field, and elevated plus maze paradigms to assess spatial memory and anxiety-like behavior. Following behavioral evaluation, animals were sacrificed, and neuronal morphology of the cortex and hippocampus was assessed using Golgi-Cox (GC) staining. <b>Results:</b> Rats treated with CBD displayed a sexually dimorphic response in spatial memory, with CBD-treated females developing a deficit but not males. CBD did not elicit alterations in anxiety-like behavior in either sex. Neonatal CBD caused an overall decrease in dendritic length and spine density (apical and basal) in cortical and hippocampal neurons in both sexes. Sholl analysis also revealed a decrease in dendritic intersections in the cortex and hippocampus, indicating reduced dendritic arborization. <b>Conclusions:</b> This study provides evidence that neonatal CBD exposure perturbs normal brain development and leads to lasting alterations in spatial memory and neuronal dendrite morphology in early adulthood, with sex-dependent sensitivity.</p>","PeriodicalId":9386,"journal":{"name":"Cannabis and Cannabinoid Research","volume":" ","pages":"e145-e155"},"PeriodicalIF":3.1,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142280572","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Endocannabinoid System as a Target for Ischemic Stroke Therapy.","authors":"Solange de Souza Stork, Khiany Mathias, David Dos Santos, Fabrício Weinheimer Lippert, Richard Simon Machado, Victor Duílio Maragno, Larissa Joaquim, Samara Souza Stork, Rafael Mariano Bitencourt, Franciane Bobinski, Fabricia Petronilho","doi":"10.1089/can.2024.0017","DOIUrl":"https://doi.org/10.1089/can.2024.0017","url":null,"abstract":"<p><p><b>Introduction:</b> Cannabinoids are increasingly being explored as a potential treatment for neurodegenerative diseases. This article aims to provide a narrative review of available data on the treatment of neurological disorders with cannabis constituents, focusing on ischemic stroke. <b>Methods:</b> Selected articles are summarized to describe design, results, limitations, conclusions, and implications about this theme. <b>Results:</b> The growing understanding of the endocannabinoid system and the cannabinoid receptors distribution in all human body systems and organs and particularly in brain structures importantly involved in myelination processes, suggests potential benefits for stroke symptoms and overall patient improvement. However, the variety of studied compounds, the different administration routes, dosages, and timing complicates data comparison, especially due to limited studies about these compounds, peculiarly in stroke patients. Thereat, this review to showcase disparities in findings and to summarize current advancements in cannabinoid use for potential future treatments. <b>Conclusion:</b> This article offers a review of the current literature in the field and discuss a pragmatic approach to the clinical use of cannabinoids in patients with ischemic stroke.</p>","PeriodicalId":9386,"journal":{"name":"Cannabis and Cannabinoid Research","volume":"10 1","pages":"38-52"},"PeriodicalIF":3.1,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143416688","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Investigating the Relationship Between Cannabis Expectancies and Anxiety, Depression, and Pain Responses After Acute Flower and Edible Cannabis Use.","authors":"Margy Y Chen, Emily B Kramer, Laurel P Gibson, L Cinnamon Bidwell, Kent E Hutchison, Angela D Bryan","doi":"10.1089/can.2023.0264","DOIUrl":"10.1089/can.2023.0264","url":null,"abstract":"<p><p><b>Objective:</b> Cannabis has been touted for a host of pharmacological and therapeutic effects and users commonly report reduced symptoms of physical and mental health conditions, including anxiety, depression, and chronic pain. While there is existing empirical evidence supporting these effects of cannabis use, little is known about the extent to which these effects result from pharmacological versus expectancy factors. We evaluated the associations between participants' cannabis expectancies and their acute self-reported reactions after using legal market forms of cannabis with varying levels of cannabidiol (CBD) and Δ9-tetrahydrocannabinol (THC) in three domains: anxiety, depression, and pain. <b>Methods:</b> Fifty-five flower and 101 edible cannabis users were randomly assigned and asked to purchase at a local dispensary one of three products containing varying levels of CBD and THC. Participants completed a baseline assessment where they reported expectancies about general health effects of cannabis use and an experimental mobile laboratory assessment where they administered their assigned products. Edible users also reported their domain-specific expectancies about cannabis use in improving anxiety, depression, and pain. Following administration, participants completed acute indicators of anxiety, depression, and pain operationalized through subjective acute tension, elation, and a single-item measure of pain. <b>Results:</b> Among flower users, more positive expectancies for cannabis to improve general health were correlated with greater reductions in tension at acute post-use. This finding was replicated among edible users. Unlike flower users, more positive expectancies for cannabis to improve general health were also correlated with greater increases in elation and greater reductions in pain among edible users. More positive expectancies for cannabis to improve depression and pain were also correlated with greater increases in elation and greater reductions in pain, respectively, among edible users. <b>Conclusions:</b> Cannabis users' expectancies significantly impacted some of the acute subjective effects of legal market cannabis products. Among both flower and edible users, consistent, significant expectancy effects were found. Results were consistent with prior findings and demonstrate the need to measure and control pre-existing expectancies in future research that involves cannabis administration. Clinical trial registration number: NCT03522103.</p>","PeriodicalId":9386,"journal":{"name":"Cannabis and Cannabinoid Research","volume":" ","pages":"71-80"},"PeriodicalIF":3.1,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140847871","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}